Clinical trial accrual targeting genomic alterations after next-generation sequencing at a non-national cancer institute-designated cancer program

Journal of Oncology Practice

Volumn 12, Issue 4, 2016, Pages e396-e404

  Mantripragada, Kalyan C ^a   Olszewski, Adam J ^a   Schumacher, Andrew ^a   Perez, Kimberly ^a   Birnbaum, Ariel ^a   Reagan, John L ^a   Mega, Anthony ^a   Khurshid, Humera ^a   Bartley, Carolyn ^a   Lombardo, Alise ^a   Rossiter, Rachael ^a   Papa, Alessandro ^a   Bakalarski, Pamela ^a   Safran, Howard ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b Newport Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BINIMETINIB; CERITINIB; DABRAFENIB; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INFIGRATINIB; RIBOCICLIB; TRAMETINIB;

ADULT; AGE; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CANCER CENTER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE TRANSLOCATION; GENERAL CONDITION DETERIORATION; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC VARIABILITY; GENOME; GENOMICS; GENOTYPE; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LEIOMYOSARCOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PANCREAS CANCER; PATIENT DECISION MAKING; PATIENT HISTORY OF THERAPY; POINT MUTATION; PROSTATE CANCER; UROGENITAL TRACT CANCER; GENE EXPRESSION PROFILING; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASM; PATIENT SELECTION; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANCER CARE FACILITIES; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; GENETIC VARIATION; GENOMICS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATIENT SELECTION; UNITED STATES;

EID: 84963935849     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2015.008433     Document Type: Article

References (24)

1. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
2. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381, 2012
3. Katayama R, Lovly CM, Shaw AT: Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: A paradigm for precision cancer medicine. Clin Cancer Res 21: 2227-2235, 2015
4. Shaw AT, Ou SH, Bang YJ, et al: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963-1971, 2014
5. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384, 2012
6. National Cancer Institute: NCI Community Cancer Centers Program. http://ncccp. cancer.gov/About/ProgramSummary.htm
7. Peguero JA, Knost JA, Bauer TM, et al: Successful implementation of a novel trial model: The signature program. J Clin Oncol 33:15s, 2015 (suppl; abstr 106)
8. Abrams J, Conley B, Mooney M, et al: National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Ed Book 71-76, 2014
9. Meric-Bernstam F, Brusco L, Shaw K, et al: Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33:2753-2762, 2015
10. Johnson DB, Dahlman KH, Knol J, et al: Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 19:616-622, 2014
11. Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023-1031, 2013
12. Foundation One: Foundation One current gene list. http://foundationone.com/genelist1.php
13. Shepherd R, Forbes SA, Beare D, et al: Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) 22011:bar018, 2011
14. Cobain EF, Robinson DR, Wu Y, et al: Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center. J Clin Oncol 33:15s, 2015 (suppl; abstr 11057)
15. Chakradhar S: Tumor sequencing takes off, but insurance reimbursement lags. Nat Med 20:1220-1221, 2014
16. Miller FA, Hayeems RZ, Bytautas JP, et al: Testing personalized medicine: Patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet 22:391-395, 2014
17. Gray SW, Hicks-Courant K, Cronin A, et al: Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol 32:1317-1323, 2014
18. Schwaederle M, Parker BA, Schwab RB, et al: Molecular tumor board: The University of California-San Diego Moores Cancer Center experience. Oncologist 19:631-636, 2014
19. Speare V, Dolinsky JS, Laduca H, et al: Germline testing in hereditary cancer genes subsequent to the identification of mutations in tumor specimens. J Clin Oncol 33:15s, 2015 (suppl; abstr 1527)
20. Gordon ES, Griffin G, Wawak L, et al: "It's not like judgment day": Public understanding of and reactions to personalized genomic risk information. J Genet Couns 21:423-432, 2012
21. Mack JW, Walling A, Dy S, et al: Patient beliefs that chemotherapy may be curative and care received at the end of life among patients with metastatic lung and colorectal cancer. Cancer 121:1891-1897, 2015
22. Prigerson HG, Bao Y, Shah MA, et al: Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1:778-784, 2015
23. Simon R, RoychowdhuryS: Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 12:358-369, 2013
24. Collins FS, Varmus H: Anew initiative on precision medicine. N Engl J Med 372: 793-795, 2015